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Ezetimibe reduces intimal hyperplasia in rabbit
jugular vein graft
Takashi Maekawa, MD, PhD,a Kimihiro Komori, MD, PhD,a Kouichi Morisaki, MD, PhD,a and
Takeo Itoh, PhD,b Nagoya City, Japan
Background: The selective cholesterol transport inhibitor ezetimibe is widely used to prevent development of atheroscle-
rosis in patients with hypercholesterolemia. However, whether this agent inhibits intimal hyperplasia in autologous vein
grafts is unknown. The present study was undertaken to clarify if ezetimibe reduces cell proliferation and intimal
hyperplasia in vein grafts.
Methods: Forty-four rabbits were randomly divided into two groups: one group received ezetimibe (0.6 mg/kg/d), and
the control group did not. Ezetimibe administration was started 1 week before rabbits underwent interposition reversed
autologous jugular vein grafts. The proliferative cells and apoptotic cells were counted in the vein grafts 14 days after
implantation, and changes in acetylcholine-induced relaxation and endothelial intracellular concentration of Ca2
([Ca2]i) were examined at 28 days.
Results: Ezetimibe reduced serum cholesterol and triglyceride. There were fewer proliferating cells in the ezetimibe group
(5.7%  0.2%, n  7) than in the control group (12.8%  0.5%, n  7; P < .0001) and more apoptotic cells in the
ezetimibe group (5.3%  0.2%, n  7) than in the control group (2.3%  0.2%, n  7; P < .0001). Intimal hyperplasia
was less in the ezetimibe group (46.1  6.0 m, n  7) than in the control group (76.0  2.5 m, n  7; P < .01).
Acetylcholine-produced endothelium-dependent relaxation was observed only in the ezetimibe group, which was blocked
by the nitric oxide (NO) synthase inhibitor N-nitro-L-arginine. Acetylcholine increased [Ca2]i only in the ezetimibe
group.
Conclusions: Ezetimibe reduced cell proliferation and enhanced cell apoptosis, thus inhibiting intimal hyperplasia in
rabbit autologous vein grafts. Ezetimibe restored the acetylcholine-induced increase in [Ca2]i in endothelial cells and
improved endothelium-dependent NO-mediated relaxation in the vein graft. Our results suggest that ezetimibe enhances
the function of endothelial NO through an increase in endothelial [Ca2]i, thus reducing vein graft intimal hyperplasia.
( J Vasc Surg 2012;56:1689-97.)
Clinical Relevance: Intimal hyperplasia is a major obstacle to patency after vein grafting. Various treatments have been
examined to reduce neointimal hyperplasia; however, a standard clinical treatment has not yet been established.We report
here that ezetimibe inhibits intimal hyperplasia in rabbit autologous vein grafts. More importantly, we demonstrated that
ezetimibe improves acetylcholine-induced endothelium-dependent relaxation by restoring its endothelial cell [Ca2]i–
mobilizing activity in the grafts. The present results suggest that ezetimibe restores agonist-induced endothelial [Ca2]i
mobilization and enhances the function of endothelium-derived nitric oxide, thus reducing intimal hyperplasia in vein
grafts. Our results support the notion that ezetimibe helps to prevent intimal hyperplasia in vein grafts.
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mSurgical revascularization using autologous vein con-
tinues to be the most commonly used option for coronary
artery bypass grafting and the surgical treatment of periph-
eral arterial disease, its main advantages being ready avail-
ability and suppleness.1,2 Such venous implants are subject
to increased shear stress, loss of endothelial cells, migration
and invasion of inflammatory cells, and migration and
proliferation of smooth muscle cells.3,4 These changes lead
to intimal hyperplasia and subsequently accelerate athero-
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http://dx.doi.org/10.1016/j.jvs.2012.05.071enesis, being responsible for vein graft occlusion.5-7 En-
othelium, through the synthesis and release of vasorelax-
ng factors, such as nitric oxide (NO) and prostacyclin, is
ritical in the regulation of vascular tone and vascular wall
tructure changes.8,9 Several studies have demonstrated the
mportance of preserving the function of endothelium-
erived NO to inhibit intimal hyperplasia in autologous
ein grafts.10-13
Ezetimibe is a potent inhibitor of sterol absorption,
hich selectively inhibits biliary and dietary cholesterol
ptake in the small intestine by blocking the Niemann-Pick
1 like 1 sterol transporter activity,14 thus lowering the
erum concentration of total cholesterol and low-density
ipoprotein cholesterol (LDL-C).15-17 Ezetimibe was also
ound to reduce monocyte chemoattractant protein-1 ex-
ression and decrease macrophage/monocyte content in
therosclerotic plaque in an atherosclerosis rabbit model.18
urthermore, ezetimibe enhances acetylcholine-induced
ndothelium-dependent relaxation through an enhance-
ent of the function of endothelium-derived NO in apoli-
oprotein E-deficient mice.19 TheHeart and Renal Protec-
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December 20121690 Maekawa et altion clinical trial20 demonstrated that lowering of LDL-C
with simvastatin plus ezetimibe safely reduced the inci-
dence of major atherosclerotic events in a wide range of
patients with advanced chronic kidney disease. Taken to-
gether, these results suggest that ezetimibe may reduce
intimal hyperplasia seen in autologous vein grafts. How-
ever, this remains to be determined.
The present study was undertaken to determine
whether long-term administration of ezetimibe was able to
inhibit intimal hyperplasia in rabbit autologous vein grafts.
Rabbits were used because this model has been used to
examine the effects of lipid-lowering agents in vein graft
hyperplasia. Next, to clarify the underlying mechanism,
acetylcholine-induced changes in endothelial intracellular
Ca2 ([Ca2]i), and endothelium-dependent relaxation in
grafted vein from rabbits treated with ezetimibe was com-
pared with that of nontreated rabbits.
METHODS
Animals and vein graft implantation. All experi-
ments performed in this study conformed to “Guidelines
on the Conduct of Animal Experiments” issued by the
Nagoya University Graduate School of Medicine and by
the Graduate School of Medical Sciences in Nagoya City
University and were approved by the Committee on the
Ethics of Animal Experiments in that institution.
The study randomly divided 44 male Japanese albino
rabbits (2.5 to 3.0 kg, supplied by Nippon SLC,
Hamamatsu, Japan) into two groups. The control group
was fed commercial rabbit chow (CR3, containing 4%
crude fat from soybean oil; CLEA Japan Inc, Tokyo, Ja-
pan), and the ezetimibe group received the CR3 chow with
0.6 mg/kg/d ezetimibe, as previously described.18 Treat-
ment with ezetimibe was initiated 1 week before vein
implantation and continued for 2 or 4 weeks until harvest
of the vein graft. The amount of chow that remained in a
cage in the morning was checked daily to ascertain the daily
amount of chow ingested by a rabbit, and the rabbits that
had ingested 50% of the food provided were omitted.
Carotid interposition reversed autologous jugular vein
grafts were performed, as previously reported.21 Anesthesia
was induced intramuscularly with ketamine hydrochloride
(50 mg/kg) and xylazine (10 mg/kg) and maintained with
the intravenous (i.v.) administration of ketamine hydro-
chloride (10 mg/kg) and xylazine (10 mg/kg) whenever
required. After a longitudinal neck incision, the right jug-
ular vein and the right common carotid artery were ex-
posed. The branches of the jugular vein were carefully
ligated with 8-0 polypropylene sutures. An approximately
2.5-cm segment of the jugular vein was taken for the
autologous reversed vein graft.
Graft harvesting was completed withmeticulous care to
avoid injuring the graft wall. The harvested graft was kept
moistened in heparinized saline (5 IU/mL) at room tem-
perature. The animals were systemically heparinized (200
IU/kg), and the internal carotid artery and two of the three
branches of the external carotid artery were ligated. The
most inferior branch of the external carotid artery served as whe only outflow for the conditions modeling poor runoff.
he common carotid artery was clamped distally and prox-
mally, and a graft was anastomosed in an end-to-end
ashion into the divided artery with interrupted 8-0 poly-
ropylene sutures under a surgical microscope. The wound
as closed layer to layer.
Harvest of implanted vein grafts. For histochemical
xamination, autologous vein grafts were harvested under
eneral anesthesia at 14 and 28 days after implantation. In
rief, rabbits were euthanized by an overdose of pentobar-
ital (50 mg/kg i.v.) and the graft was harvested after
ystemic heparinization (200 IU/kg i.v.). The harvested
raft was fixed with 4% formaldehyde at 100 mmHg for 30
inutes, perfused, and immersed in the same fixative over-
ight at room temperature. Each sample was embedded in
araffin and cut into 5-m sections.
Intimal hyperplasia was assessed in the harvested vein
rafts in each group (n  7 in each group). Three sections
ere obtained from each vein graft, and each section
as deparaffinized in a xylene/ethanol series and stained
ith hematoxylin and eosin or with elastica van Gieson.
he intimal area and medial area were measured by
ACSCOPE (Mitani Co, Fukui, Japan) at eight different
andomly selected views per section and these were aver-
ged. The three sections were examined in the same way by
hree observers who were blinded to the identity of the
roups. Values were averaged to represent the intimal
yperplasia of the vein graft per rabbit and were used for
tatistical analysis.
Immunohistochemical staining. Vein grafts (n  7
n each group) were harvested at 14 days after implantation
nd deparaffinized in a xylene/ethanol series. Proliferative
ells in the neointima were identified by immunohisto-
hemical staining with Ki-67monoclonal antibody (DAKO
ytomation Inc, Carpenteria, Calif). To determine apopto-
ic cells, we performed terminal deoxynucleotidyl trans-
erase-mediated deoxyuride-5’-triphosphate nick-end la-
eling (TUNEL) staining (Roche, Mannheim, Germany),
s previously described.22 The Ki-67-positive and TUNEL-
ositive nucleated cells in the neointima were counted
original magnification, 400) by three observers who
ere blinded to the identity of the groups. The values
btained by the three observers were averaged for each
ection. The quantitative analysis was performed for eight
ndependent sections in each rabbit. The number of Ki-67–
ositive and TUNEL-positive cells/total number of cells
ounted was defined as the Ki-67 index and TUNEL index
f the vein graft.
Isometric tension measurement. The vein graft har-
ested at 4 weeks after implantation was excised and imme-
iately placed in Krebs solution and thereafter cleaned by
emoving the connective tissues. The midportion of the
arvested graft was used in the present experiments. In
ome preparations, the endothelium was removed as de-
cribed elsewhere.23 A ring preparation (1-mmwide) was
uspended for measurement of isometric contraction in an
rgan chamber. This was set between two stainless steel
ires inserted into the lumen of the ring; one wire was
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Volume 56, Number 6 Maekawa et al 1691connected to a force transducer (UL-2 GR; Minebea Co,
Nagano, Japan) and then a carrier amplifier (AS2101;
NEC-San-ei Instruments, Tokyo, Japan).24 The output
signal was fed into an IBM/AT-compatible personal com-
puter through an analog-to-digital PowerLab converter
(AD Instruments Pty Ltd, Bella Vista, Australia). The or-
gan chamber was filled with 3 mL Krebs solution at 37°C
and gassed with 95% oxygen and 5% carbon dioxide. Rest-
ing tension was adjusted to obtain maximum contraction
induced by K solution (128 mmol/L).
To obtain concentration-dependent responses, acetyl-
choline (10 nmol/L to 3 mol/L) was cumulatively ap-
plied in an ascending order during the contraction-induced
prostaglandin F2 (PGF2, 1 mol/L) in endothelium-
intact strips. To study the influence of endothelium-derived
NO, the effects of acetylcholine were examined in the
presence and absence of the NO-synthase inhibitor N-
nitro-L-arginine (L-NNA, 0.1 mmol/L), which was applied
as pretreatment for 60 minutes and was present thereafter.
The concentration of PGF2was reduced to 0.3mol/L in
the presence of L-NNA to obtain matched amplitudes of
contraction.
The concentration–response relationship for the NO
donor NOC-7 (0.1 nmol/L to 0.1 mol/L) was obtained
by its cumulative application during the contraction in-
duced by PGF2 in endothelium-denuded strips. Guaneth-
idine (5 mol/L, to prevent effects due to release of
sympathetic transmitters) and diclofenac (3 mol/L, to
inhibit the production of cyclooxygenase products) were
present throughout the experiments.
Measurement of [Ca2]i. The concentration of
[Ca2]i was estimated using the ratiometric fluorescence
Ca2-indicator Fura 2.25 Endothelium-intact strips were
loaded with Fura 2-acetoxymethyl ester (Fura 2-AM; 5
mol/L) in Krebs solution containing 0.001% Pluronic
F-127 for 4 hours at room temperature under dark condi-
tions. After loading, the strip was mounted on a fluores-
cence microscope and superfused with warmed (37°C)
Krebs solution. Next, acetylcholine (10 nmol/L to 3
mol/L) was applied for 2minutes in ascending order with
a 10-minute interval. Fura 2 was excited by dual wave-
lengths (340 nm [F340] and 380 nm [F380]) for 182ms and
collected through a 510-nm emission filter (half-width, 20
nm) at 15-second intervals. The [Ca2]i was expressed as
the fluorescence ratio F340/F380. Themean values of F340/
F380 obtained from six endothelial cells in each strip were
averaged, and one value per strip was used for the later
analysis.
Solutions. The composition of the Krebs solution was
(mmol/L) NaCl, 122; KCl, 4.7; MgCl2, 1.2; CaCl2, 2.5;
NaHCO3, 15.5; KH2PO4, 1.2; and glucose, 11.5. The
solution was bubbled with 95% oxygen and 5% carbon
dioxide (pH, 7.3-7.4).
Drugs. The drugs used were L-NNA (Peptides Ins-
titute Inc, Osaka, Japan), acetylcholine-HCl (Daiichi-
seiyaku, Tokyo, Japan), diclofenac sodium (Sigma, St.
Louis, Mo), guanethidine (Tokyo Kasei, Tokyo, Japan), (GF2 (Cayman Chemical Co, Ann Arbor, Mich), and
ura 2-AM (Molecular Probes, Eugene, Ore).
Stock solutions were made of Fura 2-AM (1 mmol/L
n dimethylsulfoxide) and PGF2 (10 mmol/L in ethanol).
ll other drugs were dissolved in ultrapure Milli-Q water
Japan Millipore Corp, Tokyo, Japan). The stock solutions
ere stored at 80°C and diluted in Krebs solution just
efore use.
Sample size calculation. Bypass operations were done
n 44 rabbits: 22 in the control group and 22 in the
zetimibe group. The 22 rabbits in the control group were
urther separated into two groups. One group consisted of
even rabbits from which the vein grafts were harvested at
4 days after implantation for examination of cell prolifer-
tion and apoptosis, and the vein grafts in the remaining 15
abbits were taken at 28 days histochemical examination of
ntimal thickness (n  7) and for tension and endothelial
Ca2]i measurement (n  8). Similar sample size calcula-
ion was made in the ezetimibe group.
Statistical analysis. All results are expressed as mean	
tandard error of the mean, with n values representing the
umber of rabbits used (each rabbit provided one segment
or a given experiment). A one-way or two-way repeated-
easure analysis of variance, with post hoc comparisons
ade using the Scheffé procedure or the Student unpaired
-test, was used for the statistical analysis. The level of
ignificance was set at P 
 .05.
ESULTS
Intimal hyperplasia in vein graft. All animals survived
he operations, and all vein grafts were patent until the time of
arvest. Oral administration of ezetimibe for 28 days had no
ffects on body weight and serum concentration of high-
ensity lipoprotein cholesterol or glycosylated hemoglobin
HbA1c), but serum concentrations of total cholesterol,
DL-C, and triglyceride were reduced (Table I).
Fig 1, A shows the whole-mount photomicrographs of
ein grafts at 28 days after implantation obtained from a
ontrol rabbit (left panel) and a ezetimibe-treated rabbit
able I. Body weight and metabolic parameters in
ontreated rabbits and in rabbits treated with ezetimibea
ariable
Control Ezetimibe
P(n  7) (n  7)
ody weight, kg 2.75 	 0.08 2.80 	 0.03 .54
riglyceride, mg/dL 68.33 	 5.30 53.83 	 3.48 
.04
holesterol, mg/dL
Total 32.83 	 1.54 23.75 	 1.24 .0006
HDL 15.33 	 0.94 13.17 	 1.15 .15
LDL 9.00 	 0.69 4.33 	 0.45 
.0001
bA1C, % 2.59 	 0.05 2.63 	 0.05 .53
bA1c, Glycosylated hemoglobin; HDL, high-density lipoprotein; LDL,
ow-density lipoprotein.
Blood samples were collected from nontreated rabbits and rabbits treated
ith ezetimibe 4 weeks after the operation. Data are shown as mean 	
tandard error of the mean.right panel). Although both veins remain widely patent
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December 20121692 Maekawa et alafter 28 days, the vascular wall was much thicker in a
control group than in the ezetimibe-treated group (Fig 1,
B). Intimal thickness and the intima/media index of the
vein graft were significantly less in the ezetimibe group than
in the control group (n 7; P
 .01; Table II), but medial
thickness and total lumen area did not differ significantly
between the two groups (Table II).
Cell proliferation and apoptosis in vein graft. In the
Fig 1. Effects of ezetimibe are shown on the developme
after operation. A,Microscopic findings in the middle po
the ezetimibe group (right panel; elastica van Gieson s
indicate the internal elastic lamina (elastica van Gieson s
Table II. Morphometric analysisa
Variable
Control Ezetimibe
P(n  7) (n  7)
Lumen area, mm2 9.5 	 0.7 9.9 	 0.7 .73
Intimal thickness, m 76.0 	 2.5 46.1 	 6.0 
.01
Medial thickness, m 65.2 	 3.9 58.3 	 1.0 .11
Intima/media index 1.2 	 0.1 0.8 	 0.1 
.01
aData are shown as mean 	 standard error of the mean.neointimal region, the Ki-67 index was significantly smaller (n the ezetimibe group (5.7% 	 0.2%) than in the control
roup (12.8%	 0.5%, n  7 in each group; P
 .0001; Fig
, A and B). The TUNEL index in the neointimal region
as significantly bigger in the ezetimibe group (5.3% 	
.2%) than in the control group (2.3% 	 0.2%, n  7 in
ach group; P 
 .0001; Fig 2, C and D).
Effects of ezetimibe on acetylcholine-induced
elaxation. There was no significant difference in the am-
litude of contraction induced by K (128 mmol/L) in
ndothelium-intact strips between the control group (n 
) and the ezetimibe group (n  7; P  .05; Fig 3, A and
). The NO synthase inhibitor L-NNA significantly en-
anced the contraction induced by K (128 mmol/L) to
he same extent in the two groups, suggesting that the
unction of spontaneously released endothelial NO is not
odified by ezetimibe (Fig 3, B).
In endothelium-intact strips, acetylcholine (10
mol/L to 3 mol/L) did not produce a relaxation during
he contraction induced by PGF in the control group
intimal hyperplasia in autologous vein grafts at 28 days
of the vein graft from the control group (left panel) and
g [original magnification, 20]). B, The arrowheads
g [original magnification,  400]).nt of
rtion
tainin2
n  8), but acetylcholine induced concentration-depen-
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Volume 56, Number 6 Maekawa et al 1693dent relaxation in the ezetimibe group (n  6; P 
 .0001;
Fig 3, C). The acetylcholine-induced relaxation in the
ezetimibe group (n  6) was blocked by the NO synthase
inhibitor L-NNA (0.1 mmol/L; P 
 .0001) vs the
ezetimibe group before L-NNA (L-NNA(–) Fig 3, C).
Effects of ezetimibe on NOC-7-induced relaxa-
tion. In endothelium-denuded preparations, NOC-7
(0.1 nmol/L to 0.1 mol/L) induced a concentration-
dependent relaxation during the contraction induced by
PGF2; however, there was no significant difference be-
tween the control group and the ezetimibe group (n 5 in
each group; P  .05; Fig 3, D).
Effects of ezetimibe on acetylcholine-induced
[Ca2]i increase in endothelial cells. Under basal con-
ditions, the Fura-2 ratio in endothelial cells of the vein
grafts was 1.19 	 0.03 in the control group (n  5) and
1.21	 0.07 in the ezetimibe group (n 8; P .05; Fig 4,
Bb1). Acetylcholine (10 nmol/L to 3 mol/L) did not
modify the endothelial [Ca2]i in the control group but
concentration-dependently increased the [Ca2]i in endo-
thelial cells in the ezetimibe group (n 5-8; P
 .0001; Fig
Fig 2. Effects of ezetimibe on proliferative activity and a
operation.A, Representative Ki-67 staining in the middle
panel) or rabbits treated with ezetimibe (right panel;
Ki-67–positive cells in the neointima. B, Graph shows K
rabbits treated with ezetimibe (n  7 in each group).
deoxynucleotidyl transferase-mediated deoxyuride-5’-tri
of the vein graft from nontreated control rabbits (left p
magnification,  400). The arrowheads indicate TUNE
shown in vein grafts from nontreated control rabbits or ra
standard error of the mean (error bars). *P 
 .05 vs con4, Bb2). oISCUSSION
We found that long-term administration of ezetimibe
educed intimal hyperplasia in rabbit autologous vein
rafts. Acetylcholine did not induce relaxation in the vein
rafts of the control group. However, acetylcholine did
nduce the endothelium-dependent relaxation in the
zetimibe group, which was blocked by the NO synthase
nhibitor L-NNA. More importantly, we found that acetyl-
holine increased [Ca2]i in endothelial cells in the
zetimibe group but not in the control group. In addition,
zetimibe treatment did not modify smooth muscle relax-
tion induced by the NO donor NOC-7 in the graft. These
esults indicate that sustained administration of ezetimibe
mproves acetylcholine-induced endothelium-dependent
O-mediated relaxation through an enhancement of ace-
ylcholine-induced endothelial [Ca2]i mobilization in
abbit autologous vein grafts.
Venous adaptation to the arterial environment is char-
cterized by thickening of the intima, media, and adventi-
ia.26,27 These modifications, which result from deposition
sis in neointima of autologous vein grafts at 14 days after
ion of the vein graft from nontreated control rabbits (left
inal magnification,  400). The arrowheads indicate
index in vein grafts from nontreated control rabbits or
epresentative photomicrographs stained with terminal
hate nick-end labeling (TUNEL) in the middle portion
or rabbits treated with ezetimibe (right panel; original
sitive cells in the neointima. D, The TUNEL index is
treated with ezetimibe. Results are expressed as mean	popto
port
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3-7,26,27
This remodeling appears to involve at least two distinct
temporal phases: lumen-outward remodeling at an earlier
phase and wall-stiffness changes at the later phase.27 The
earlier phase is suggested to be important for successful
adaptation to increase diameter and wall thickness in hu-
man vein grafts. We found that ezetimibe not only reduced
the number of proliferating cells but also increased the
number of apoptotic cells, thus inhibiting intimal hyperpla-
sia in autologous vein grafts at 14 days after implantation.
Furthermore, in the vein grafts at 28 days after implanta-
tion, intimal thickness was less in the ezetimibe group than
in the control group, although the total lumen area and
medial thickness were comparable between the two groups.
These results indicate that long-term administration of
ezetimibe selectively inhibits the development of intimal
hyperplasia in rabbit autologous vein grafts.
Endothelial cells are suggested to play an essential role
in regulation of intimal growth in vein grafts through the
synthesis and release of NO.28 The NO synthesis by endo-
Fig 3. Effects of ezetimibe on high K-induced contra
gous vein grafts and the effects on NOC-7–induced relax
of the mechanical responses induced by high K (128 m
(L-NNA) was applied for 60 minutes, and high-K and A
L-NNA in endothelium-intact strips from nontreated
Acetylcholine, at concentrations of (1) 10 nM, (2) 30 n
applied during a contraction induced by prostaglandin F
before and after application of L-NNA in the vein graft fr
ezetimibe (n 7). C, Summary of the effects of ezetimib
by PGF2 before application of acetylcholine was normali
group; n  6, ezetimibe group). L-NNA(–), Before app
Results are expressed as mean 	 standard error of the m
ezetimibe; †††P 
 .001 L-NNA(–) in control vs L-NNAthelial NO synthase is activated through an increase in iCa2]i.
29 We previously found that the increased intimal
hickness in autologous vein grafts was closely related to the
oss of acetylcholine-induced endothelium-dependent
O-mediated relaxation, although changes in agonist-
nduced endothelial [Ca2]i mobilization were not mea-
ured.2,10-13 We also found that such hyperplasia was re-
uced by endothelial NO synthase gene transfer13 or oral
dministration of the NO precursor L-arginine.12 Inter-
stingly, endothelium-derived NO inhibited leukocyte-
ndothelial interaction,30,31 platelet adhesion and aggrega-
ion,32 and smooth muscle cell proliferation.33 Here, we
ound that in endothelium-intact vein grafts, the NO syn-
hase inhibitor L-NNA enhanced the high K-induced
ontraction in the control and ezetimibe groups, and the
agnitude of the response was similar between the two
roups (Fig 3, B). Furthermore, resting endothelial
Ca2]i was similar between the two groups (Fig 4, Bb1),
uggesting that long-term administration of ezetimibe
ay not modify the function of spontaneously released
ndothelial NO in rabbit autologous vein grafts. Most
and acetylcholine (ACh)-induced relaxation in autolo-
in endothelium-denuded vein grafts. A, After recording
d acetylcholine (10 nM to 3 M), N-nitro-L-arginine
duced responses were again obtained in the presence of
ol rabbits (a) or rabbits treated with ezetimibe (a2).
) 0.1 M, (4) 0.3 M, (5) 1 M, and (6) 3 M, was
F2). B, The absolute tension induced by 128 mM K
ontreated control rabbits (n 7) or rabbits treated with
ACh-induced responses. The tonic contraction induced
s the relative tension of 1.0 for each strip (n 8, control
on of L-NNA; L-NNA(), after application of L-NNA.
***P 
 .001 L-NNA(–) in ezetimibe vs L-NNA() in
ezetimibe.ction
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Volume 56, Number 6 Maekawa et al 1695ezetimibe restored acetylcholine-induced endothelial
cell [Ca2]i increase in rabbit autologous vein grafts.
Ezetimibe also greatly improved acetylcholine-induced
endothelium-dependent NO-mediated relaxation in the
vein graft.
These results are the first to suggest that long-term
administration of ezetimibe restores agonist-induced endo-
thelial cell [Ca2]i mobilization and thereafter enhances
the function of endothelium-derived NO, thus reducing
intimal hyperplasia in rabbit autologous vein grafts. How-
ever, whether ezetimibe enhances acetylcholine-induced
endothelium-dependent vascular relaxation under the con-
dition in which the synthesis of NO is blocked in vivo
remains to be clarified.
Ezetimibe is thought to selectively block uptake of
biliary and dietary cholesterol in the small intestine and
decrease circulating levels of atherogenic lipoproteins, thus
Fig 4. Effects of ezetimibe on acetylcholine (ACh)-indu
grafts. A, Fluorescence ratio (F340/F380) images of the
group (left panel) and in the ezetimibe group (right pan
significantly in basal [Ca2]i; (b2) concentration-depend
change in [Ca2]i is expressed as Fura 2 ratio (F340/F3
shown as mean 	 standard error of the mean. ***P 
 .0reducing atherosclerosis.34 Furthermore, in addition to this teneficial lipid-lowering effect, the other direct or indirect
ascular protective actions of ezetimibe have been sug-
ested in apolipoprotein E-deficient mice.19 Here, we
ound that ezetimibe reduced serum concentrations of
otal cholesterol, LDL-C, and triglyceride and restored
cetylcholine-induced increase of endothelial cells [Ca2]i
n autologous vein graft. Because the amount of ezetimibe
sed in the present experiments (0.6 mg/kg/d) is slightly
reater than that used in patients (10 mg/d), future study
hould clarify whether this higher concentration may play a
ignificant role in the ezetimibe-induced beneficial vascular
ffects.
Hypercholesterolemia was found to impair agonist-
nduced endothelial [Ca2]i mobilization and endothelium-
ependent relaxation in rabbit femoral artery.35 At present,
owever, we do not know whether ezetimibe improves
cetylcholine-induced endothelial cell [Ca2] mobiliza-
crease in intracellular [Ca2]i in endothelial cells of vein
-sensitive dye Fura 2 in endothelial cells in the control
, Effects on [Ca2]i: (b1) the two groups did not differ
fect of ACh 10 nM to 3 Mon endothelial [Ca2]i. The
 5, control group; n  8, ezetimibe group). Data are
s control.ced in
Ca2
el). B
ent ef
) (ni
ion simply due to its cholesterol-lowering effect in rabbit
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1
1
1
1
1
2
2
2
2
2
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2
2
2
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December 20121696 Maekawa et alautologous vein grafts. This remains to be clarified in future
studies.
CONCLUSIONS
Long-term administration of ezetimibe inhibited inti-
mal hyperplasia due to reduction of cell proliferation and
enhancement of cell apoptosis in rabbit autologous vein
graft. This ezetimibe treatment restored acetylcholine-
induced endothelial cell [Ca2]i increase and endothelium-
dependent NO-mediated relaxation in the vein graft. Thus,
we suggest that the increased function of endothelium-
derivedNOmay play a role in ezetimibe-induced inhibition
of intimal hyperplasia in the vein graft. This novel finding
may facilitate the clinical usage of ezetimibe to prevent the
late graft failure after bypass grafting.
We thank Dr Junko Kajikuri for continuing help to
perform the presented experiments.
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